Order Online! Now! Get your $50 coupon for online order.Order Online! Now! Get your $50 coupon for online order.
Cancer Prevention Month: Get ACRO Health Gift Cards! Cancer Prevention Month: Get ACRO Health Gift Cards!
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Fill out organ-on-a-chip questionnaire to win a FREE gift! Fill out organ-on-a-chip questionnaire to win a FREE gift!
Biotinylated Human CTLA-4, His,Avitag (Cat. No. CT4-H82E3) captured on Biotin CAP - Series S sensor Chip can bind Yervoy (Ipilimumab) with an affinity constant of 0.635 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Cadonilimab | AK-104 | Approved | Zhongshan Akeso Biopharma Co Ltd | 开坦尼 | Mainland China | Uterine Cervical Neoplasms | Kangfang Pharmaceutical Co Ltd | 2022-06-29 | Microsatellite Instability; Adenocarcinoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Esophageal Squamous Cell Carcinoma; Colorectal Neoplasms; DNA Repair-Deficiency Disorders; Urologic Neoplasms; Vulvar Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Microsatellite instability-high cancer; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Triple Negative Breast Neoplasms; Vaginal Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Carcinoma; Lymphoma, T-Cell, Peripheral | Details |
Tremelimumab | CP-675206; CP-675 | Approved | Pfizer Inc | IMJUDO | United States | Carcinoma, Hepatocellular | Astrazeneca Ab | 2022-10-21 | Urogenital Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Vulvar Neoplasms; Urethral Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Oropharyngeal Neoplasms; Ureteral Neoplasms; Peritoneal Neoplasms; Genital Neoplasms, Female; Carcinoma, Squamous Cell; Mouth Neoplasms; Prostatic Neoplasms; Gallbladder Neoplasms; Esophageal adenocarcinoma; Glioma; Lung Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Hepatitis C, Chronic; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Endometrioid; Cystadenoma, Serous; Solid tumours; Head and Neck Neoplasms; Hematologic Neoplasms; Bone metastases; Kidney Neoplasms; Biliary Tract Neoplasms; Ovarian Neoplasms; HIV Infections; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Vaginal Neoplasms; Carcinoma; Liver Neoplasms; Cystadenocarcinoma, Serous; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Neopl | Details |
Ipilimumab | BMS-734016; 10D1; MDX-CTLA-4; Anti-CTLA-4 Mab; Mab-10D14; MDX-101; MDX-010 | Approved | Bristol-Myers Squibb Company | Yervoy, 逸沃 | United States | Melanoma | Bristol-Myers Squibb Company | 2011-03-25 | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Neoplasms, Gonadal Tissue; Choriocarcinoma; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Brain metastases; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Sezary Syndrome; Carcinoma, Embryonal; Primary Myelofibrosis; Testicular Neoplasms; Colorectal Neoplasms; Nasopharyngeal Carcinoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sarcoma; Lymphoma, Mantle-Cell; Neuroblastoma; Lymphoma, Follicular; Carcinoma, Non-Small-Cell Lung; Mycosis Fungoides; Leukemia, T-Cell; Leukemia, Large Granular Lymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasms, Germ Cell and Embryonal; Uterine Cervical Neoplasms; Endodermal Sinus Tumor; Carcinoma, Hepatocellular; Neoplasm Metastasis; Breast Neoplasms; Adenocarcinoma; Melanoma; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, Large-Cell, Anaplastic; Burkitt Lymphoma; Intraocular Lymphoma; Lymphoma; Leukemia, Myeloid, Acute; Carcinoma, Merkel Cell; Myelodysplastic S | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Bavunalimab | XmAb-22841; XmAb-841 | Phase 2 Clinical | Xencor Inc | Cholangiocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Fallopian Tube Neoplasms; Penile Neoplasms; Endometrial Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Prostatic Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
Anti-CTLA-4/PD-1 expressing EGFR-CAR-T | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Solid tumours | Details | |
KN-044 | KN-044 | Phase 1 Clinical | Suzhou Alphamab Co Ltd | Solid tumours | Details |
PD-L1 antibody combined with CTLA-4 antibody (Shanghai Zhongshan Hospital) | Phase 2 Clinical | Shanghai Zhongshan Hospital | Cholangiocarcinoma | Details | |
GI-101 | SIM-323; SIM323; GI-101 | Phase 2 Clinical | GI Innovation Inc | Solid tumours; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Vaginal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Vulvar Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis | Details |
BMS-986288 | BMS-986288 | Phase 2 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Neoplasms | Details | |
ATOR-1015 | ADC-1015; ATOR-1015 | Phase 1 Clinical | Alligator Bioscience Ab | Solid tumours; Neoplasms | Details |
TG-6050 | TG-6050 | Phase 1 Clinical | Transgene Sa | Carcinoma, Non-Small-Cell Lung | Details |
SAL-008 | SAL-008 | Phase 1 Clinical | Xinlitai (Chengdu) Biological Technology Co Ltd | Neoplasms | Details |
BMS-986218 (Bristol-Myers Squibb) | BMS-986218 | Phase 2 Clinical | Bristol-Myers Squibb Company | Solid tumours; Liver Neoplasms; Adrenal Gland Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Lung Neoplasms | Details |
Botensilimab | AGEN-1181 | Phase 2 Clinical | Agenus Inc | Colonic Neoplasms; Melanoma; Uterine Cervical Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Neoplasms; Fibrolamellar hepatocellular carcinoma; Rectal Neoplasms; Hemangiosarcoma; Carcinoma, Renal Cell; Solid tumours | Details |
Anti-CTLA-4 monoclonal antibody (Regeneron) | REGN-4659 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung | Details |
Ipilimumab biosimilar (Mab-Venture/ShuangLu Pharmaceutical) | MV-049 | Phase 1 Clinical | Beijing Sl Pharmaceutical Co Ltd, Mab-Venture Biopharm Co Ltd | Solid tumours | Details |
BT-001 | BT-001 | Phase 2 Clinical | Transgene Sa | Carcinoma, Merkel Cell; Triple Negative Breast Neoplasms; Neoplasms; Sarcoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
SI-B003 | SI-B003 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma | Details |
Ipilimumab biosimilar (Innovent Biologics) | IBI-310 | Phase 3 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Biliary Tract Neoplasms; Liver Neoplasms; Esophageal Neoplasms; Colonic Neoplasms; Neuroendocrine Tumors; Microsatellite Instability; Nasopharyngeal Carcinoma; Bile Duct Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Firastotug | ADG-116 | Phase 2 Clinical | Adagene (Suzhou) Ltd | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
CS-1002 | SHR-8068; CS-1002 | Phase 2 Clinical | Cstone Pharmaceuticals | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
BAT-4706 | BAT-4706 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Melanoma | Details |
Vudalimab | XmAb-20717; XmAb-717; XmAb 717 | Phase 2 Clinical | Xencor Inc | Thymoma; Adenocarcinoma, Clear Cell; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Vulvar Neoplasms; Prostatic Neoplasms; Astrocytoma; Colorectal Neoplasms; Endometrial Neoplasms; Microsatellite instability-high cancer; Carcinoma, Neuroendocrine; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Thyroid Neoplasms; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Carcinoma, Basal Cell; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Hodgkin Disease; Colonic Neoplasms; Adenoma, Acidophil; Mesothelioma; Adnexal Diseases; Prostatic Neoplasms, Castration-Resistant | Details |
Evalstotug | CAB-CTLA-4; BA-3071 | Phase 2 Clinical | Bioatla, Beigene Ltd | Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular | Details |
BCD-217 | BCD-217 | Phase 3 Clinical | Biocad | Melanoma | Details |
CD-200-AR-L | CD-200-AR-L; hP-1-A-8 | Phase 1 Clinical | University Of Minnesota | Glioblastoma | Details |
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) | Phase 2 Clinical | Changhai Hospital Of Shanghai | Pancreatic Neoplasms | Details | |
Quavonlimab | MK-1308; AK-107 | Phase 2 Clinical | Zhongshan Akeso Biopharma Co Ltd, Merck Sharp & Dohme Corp | Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
SKB-337 | SKB337; A-337; SKB-337 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
MT-8421 | MT-8421; CTLA-4 ETB | Phase 1 Clinical | Molecular Templates Inc | Mismatch Repair Deficient Cancer; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Microsatellite instability-high cancer; Mesothelioma; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Gotistobart | ONC-392; BNT316; BNT-316 | Phase 3 Clinical | Oncoimmune Inc | Prostatic Neoplasms, Castration-Resistant; Carcinoma, Hepatocellular; Adenocarcinoma; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Sarcoma; Prostatic Neoplasms; Breast Neoplasms; Carcinoma, Adenoid Cystic; Head and Neck Neoplasms; Salivary Gland Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Anorectal disorders; Cystadenocarcinoma, Serous; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Solid tumours; Ovarian Neoplasms | Details |
Abatacept (Orban Biotech) | Phase 2 Clinical | Orban Biotech, The National Institute Of Diabetes And Digestive And Kidney Diseases | Diabetes Mellitus, Type 1 | Details | |
Sovipostobart | BMS-986249 | Phase 2 Clinical | Cytomx Therapeutics Inc | Neoplasms | Details |
Lorigerlimab | MGD-019; AEX1344 | Phase 2 Clinical | Macrogenics Inc | Solid tumours; Liver Neoplasms; Skin Melanoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Erfonrilimab | KN046; KN-046 | Phase 3 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd | Colorectal Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Thymoma; Esophageal Squamous Cell Carcinoma; Lymphoma; Solid tumours; Thymus Neoplasms; Breast Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Biliary Tract Neoplasms | Details |
FPT-155 | CD80-Fc; FPT-155 | Phase 1 Clinical | Five Prime Therapeutics Inc | Solid tumours | Details |
IMM-27M | IMM27M; IMM-27M | Phase 1 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Solid tumours; Neoplasms; Pathologic Processes | Details |
JS-007 | JS-007 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours; Neoplasms; Lung Neoplasms; Melanoma | Details |
TWP-102 | TWP-102 | Phase 1 Clinical | Therawisdom Biopharma Co Ltd | Neoplasms | Details |
Porustobart | HBM-4003; HCAb 4003-2 | Phase 2 Clinical | Harbour Biomed | Solid tumours; Neoplasms; Neuroendocrine Tumors; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
Muzastotug | ADG-126 | Phase 2 Clinical | Adagene Inc | Solid tumours; Liver Neoplasms; Neoplasms; Neoplasm Metastasis | Details |
KM602 | KM602; KM-602; XZP-KM602 | Phase 1 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Solid tumours | Details |
STW204/Gotistobart | AI-061 | Phase 1 Clinical | Oncoc4 Inc | Bile Duct Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Melanoma; Carcinoma, Hepatocellular; Endometrial Neoplasms; Fallopian Tube Neoplasms; Colorectal Neoplasms; Carcinoma, Renal Cell; Peritoneal Neoplasms; Urinary Bladder Neoplasms; Digestive System Neoplasms; Stomach Neoplasms; Anus Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Cystadenocarcinoma, Serous | Details |
Ipilimumab biosimilar (Henlius) | HLX13 | Phase 1 Clinical | Shanghai Henlius Biotech Inc | Liver Neoplasms; Solid tumours; Esophageal Neoplasms; Carcinoma, Renal Cell; Mesothelioma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma | Details |
RP-3 | RP-3 | Phase 2 Clinical | Replimune Inc | Solid tumours; Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Hepatocellular | Details |
YH-001 | YH-001 | Phase 2 Clinical | Eucure Pharmaceutical Technology (Beijing) Co Ltd | Liver Neoplasms; Solid tumours; Sarcoma; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
XTX-101 | XTX-101 | Phase 2 Clinical | Xilio Development Inc | Solid tumours | Details |
JK-08 | JK-08 | Phase 2 Clinical | Xinlitai (Chengdu) Biological Technology Co Ltd | Solid tumours; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma; Neoplasm Metastasis | Details |
B7-2/GM-CSF cancer gene therapy | CIT | Phase 1 Clinical | Radient | Neoplasms | Details |
RP-2 | RP-2 | Phase 2 Clinical | Replimune Group Inc, Bristol-Myers Squibb Company | Neoplasms; Colorectal Neoplasms | Details |
Recombinant anti-CTLA-4 human monoclonal antibody (Hualan Biological Engineering) | Phase 2 Clinical | Hualan Genetic Engineering Co Ltd | Melanoma | Details | |
KD-6001 | KD-6001 | Phase 2 Clinical | Shanghai Kanda Bio-Technology Co Ltd, Shanghai Celgen Bio-Pharmaceutical Co Ltd | Liver Neoplasms; Solid tumours; Neoplasms; Melanoma; Carcinoma, Hepatocellular | Details |
Zalifrelimab | AGEN-1884; RebmAb-600; UGN-301 | Phase 2 Clinical | 4-Antibody, Ludwig Institute For Cancer Research | Solid tumours; Carcinoma; Hemangiosarcoma; Urinary Bladder Neoplasms; Sarcoma; Urologic Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Pembrolizumab/Quavonlimab | MK-1308A | Phase 3 Clinical | Merck Sharp & Dohme Corp, Msd Ireland (Carlow), MSD R&D(China)Co Ltd | Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma | Details |
GIGA-564 | GIGA-564 | Phase 1 Clinical | GigaGen Inc | Solid tumours; Neoplasms | Details |
Volrustomig | MEDI-5752; MEDI5752 | Phase 3 Clinical | Medimmune Llc | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Mesothelioma; Sarcoma; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.